Evidence Review
Body Composition (Human RCTs)
Cha et al. (2012) randomized 51 overweight adults to 9.9 g/day dried doenjang or placebo for 12 weeks in a double-blind design. The doenjang group showed significant reductions in body weight (−1.0 kg, p<0.05) and visceral fat area on CT (p<0.05), with no significant change in total or subcutaneous fat areas, serum lipid profile, or self-reported dietary intake. Sample size is modest and the trial was industry-supported, but the visceral-fat selectivity is mechanistically interesting and has held up in follow-up work [1].
Cha et al. (2014) extended this in a 12-week RCT stratified by PPAR-γ2 C1431T genotype (60 enrolled, 51 completers). Visceral fat reduction was significant only in T-allele carriers, while antioxidant biomarkers (catalase, total radical clearance) responded mainly in C-allele carriers. Plasma free fatty acid, insulin, and HOMA-IR rose modestly in the doenjang arm, complicating the metabolic story. The genotype-stratified design is unusual and the subgroups are small, but the effect modification is biologically plausible given PPAR-γ's role in adipocyte biology [2].
Han et al. (2024) randomized 56 perimenopausal women across three doenjang variants (traditional high-dose, traditional low-dose, commercial). All three reduced the Kupperman menopausal symptom index, with the largest decrease in the traditional low-dose group. Traditional doenjang lowered LDL cholesterol; commercial did not. Microbiome analysis showed Bacteroidetes increases in traditional high-dose and commercial groups. The trial is small and short, but the head-to-head comparison of traditional versus commercial preparations is one of the few in the literature, and it consistently favors traditional fermentation [7].
Blood Pressure and Metabolic Syndrome
Jeong et al. (2023) analyzed 58,701 adults (20,293 men; 38,408 women) from a Korean hospital-based cohort, classifying jang intake from food frequency data and adjusting for sodium and total energy. Daily jang intake was inversely associated with metabolic syndrome (especially waist circumference, body fat, and hypertension) in men, and with hypo-HDL cholesterolemia in women. Effects persisted after sodium adjustment, suggesting the association is not driven by salt substitution alone. As cross-sectional data, this cannot establish causation, but the size and direction are consistent with the smaller intervention work [6].
Mun et al. (2019) fed Sprague-Dawley rats a high-salt diet (HS) or HS plus doenjang (HSD) for 5 weeks (n=6 per group). HSD significantly reduced systolic blood pressure versus HS alone, with increased urinary and fecal sodium and potassium excretion and reduced plasma renin. The renin finding parallels what nattokinase trials show in humans, suggesting renin-angiotensin-aldosterone system (RAAS) modulation is a shared mechanism across fermented soybean foods [4].
Anticancer and Antimetastatic (Animal/In Vitro)
Jung et al. (2006) compared doenjang aged 3, 6, and 24 months in sarcoma-180 transplanted mice and a colon-26 lung metastasis model. Twenty-four-month doenjang produced two- to three-fold greater tumor inhibition than shorter-aged paste, increased splenic NK cell activity, and raised hepatic glutathione S-transferase. The mechanistic interpretation is that long aging concentrates aglycone isoflavones, melanoidins, and peptide breakdown products that drive Phase II detox enzyme induction [5]. This is animal evidence; doenjang's anticancer signal in humans is limited to ecological and case-control associations.
Gut Microbiome (Mouse Model)
Jang et al. (2014) administered doenjang to mice and observed reduced Firmicutes-to-Bacteroidetes ratio, increased Bifidobacterium, Akkermansia, Lactobacillus, and Odoribacter, decreased Enterobacteriaceae, suppressed bacterial β-glucuronidase, lowered circulating lipopolysaccharide, and increased IL-10 and PPAR-γ expression. The shifts are coherent with metabolic-syndrome-protective microbiome signatures from independent studies. Mouse-to-human translation is uncertain, but the direction overlaps with what the cohort and RCT data suggest at the phenotype level [3].
Limitations and Open Questions
- Sodium load is real. Even traditional doenjang is around 11–14% salt by weight. The cohort signal that jang reduces hypertension risk is robust, but it depends on doenjang replacing — not supplementing — other sodium sources.
- Trial sizes are small. Most human RCTs have fewer than 60 completers and run 12 weeks or less. Long-term endpoint data on cardiovascular events, cancer, or all-cause mortality with doenjang specifically are not available; what we have is biomarker-level evidence and population correlations.
- Traditional vs. commercial matters. The two head-to-head comparisons (Han 2024; aging-time studies) both favor longer-fermented traditional preparations. Off-the-shelf supermarket doenjang in Korea is mostly gaeryangsik — short-aged single-strain product — and may not deliver equivalent effects.
- Genotype interaction. The PPAR-γ2 stratification result is one of very few examples of nutrigenomic effect modification for a fermented food. It needs replication before clinical use.
Overall evidence quality: Moderate for body composition (two small RCTs, consistent direction). Moderate-to-strong for the metabolic-syndrome association (very large cohort, sodium-adjusted, biologically plausible mechanism). Mechanistic for blood pressure and microbiome (animal models converging on RAAS and microbiome pathways). Preliminary for anticancer effects.